Hjem › Lungekreft › Michigan › Lansing
Kliniske studier for Lungekreft i Lansing, MI
11 studier for Lungekreft søker deltakere på steder i og rundt Lansing (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- University of Michigan Health - Sparrow Lansing, Lansing
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RekruttererFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekruttererFase 3
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
- University of Michigan Health - Sparrow Lansing, Lansing
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Michigan Health - Sparrow Lansing, Lansing
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Michigan Health - Sparrow Lansing, Lansing
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- University of Michigan Health - Sparrow Lansing, Lansing
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Lansing
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Washington, DC41 studier
- Arlington, VA41 studier
- Chicago, IL41 studier
- Nashville, TN40 studier
- Baltimore, MD40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Lansing
- Prostatakreft10 studier
- Brystkreft10 studier
- Ikke-småcellet lungekreft9 studier
- Kreft (alle typer)6 studier
- Larynxcancer5 studier
- Blærekreft5 studier
- Sykdommer med overdreven søvnighet5 studier
- Kolorektal kreft4 studier
- Nyrekreft (nyrecellekarcinom)4 studier
- Tykktarmskreft4 studier
- Urotelial (overgangscelle) karcinom4 studier
- Plateepitelcancer i hode og hals4 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.